The ribonucleoprotein (RNP) p67 antigen was purified from rabbit thymus and used in an enzyme linked immunosorbent assay (ELISA) with low interassay variability to detect IgG antibodies to p67 in patients with autoimmune connective tissue diseases. These antibodies were found in eight (80%) patients with a clinical diagnosis of mixed connective tissue disease (MCTD) but also in 27 (40%) patients with systemic lupus erythematosus (SLE). Sixty six per cent of the 12 patients with SLE with high levels of antibodies to p67 (>50 U) had three or more features of MCTD, including myositis, fibrosing alveolitis, Raynaud's phenomenon, and sclerodactyly. Antibodies to the p67 RNP were not associated with the presence or absence of renal disease in the patients with SLE. This study suggests that antibodies against the p67 RNP are markers for clinical features of MCTD even in the context of SLE.
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The ribonucleoprotein (RNP) p67 antigen was purified from rabbit thymus and used in an enzyme linked immunosorbent assay (ELISA) with low interassay variability to detect IgG antibodies to p67 in patients with autoimmune connective tissue diseases. These antibodies were found in eight (80%) patients with a clinical diagnosis of mixed connective tissue disease (MCTD) but also in 27 (40%) patients with systemic lupus erythematosus (SLE). Sixty six per cent of the 12 patients with SLE with high levels of antibodies to p67 (>50 U) had three or more features of MCTD, including myositis, fibrosing alveolitis, Raynaud's phenomenon, and sclerodactyly. Antibodies to the p67 RNP were not associated with the presence or absence of renal disease in the patients with SLE. This study suggests that antibodies against the p67 RNP are markers for clinical features of MCTD even in the context of SLE.
(Ann Rheum Dis 1992; 51: [1313] [1314] [1315] [1316] [1317] High titres of antibodies to nuclear ribonucleoprotein (nRNP) in the absence of antibodies to Sm are reported to occur in 95-100% of patients with mixed connective tissue disease (MCTD) but rarely in patients with systemic lupus erythematosus (SLE) and progressive systemic sclerosis.' Serum samples that have antibodies to the RNP antigen immunoprecipitate Ul snRNA-protein complexes, which contain a set of at least nine proteins denoted p67 and A-G.2 3 Antibodies to nRNP bind to three polypeptides in this complex: p67, A, and C (molecular weight 67, 33, and 20 kilodaltons respectively).4 5 Antibodies against the A and C polypeptides are found in patients with MCTD and SLE, but it has been suggested that antibodies to p67 are restricted to patients with MCTD.3 5 6 Current techniques of autoantibody detection such as immunodiffusion, passive haemagglutination,7 or counterimmunoelectrophoresis' measure the total amount of antibodies to RNP against all three peptides p67, A, and C. Direct detection of antibodies to individual specific RNP polypeptides has been achieved by immunoblotting4 6 9 10 and enzyme linked immunosorbent assay (ELISA) using natural antigen'' or recombinant antigen. 12 13 The aim of this study was to examine the possibility of using naturally occurring RNP p67 antigenic polypeptide in an ELISA for the routine detection and measurement of antibodies to p67, and to investigate the clinical correlations of this antibody in patients with SLE. The p67 antigens were diluted with phosphate 2) .
CLINICAL FEATURES OF PATIENTS WITH SLE WITH ANTIBODIES TO p67
Patients with SLE were assessed for the presence of renal disease and the major clinical features of MCTD,7 and then separated according to the presence or absence of antibodies against the p67 antigen (table 3) . This showed that the incidence of renal disease, lung fibrosis, arthritis, and Raynaud's phenomenon was similar in the two groups, but that the antibodies to p67 were detected more often when myositis was a feature of the SLE (p=0-019). The mean antibody titre to p67 was also significantly higher in patients with myositis (122 U) than those without (31 U) (p=0O003 using the F test). In addition, in the patients with SLE with features of MCTD (alveolitis, Raynaud's phenomenon, myositis, and arthritis) the mean antibody titre to p67 was higher (167 U) than in those without these clinical features (33 U) (p<0-001). In the initial description of MCTD it was thought that the presence of high titres of antibodies to the nRNP antigen could be used as a serological marker for this distinct connective tissue disease.7 Low levels of antibodies to RNP can be detected in many patients with other connective tissue diseases, however, as well as in a small percentage of normal subjects. 4 Early studies using immunoblotting suggested that the antibodies against the p67 antigen were found only in patients with MCTD and not in patients with SLE.3 5 6 Our study aimed to investigate the occurrence of antibodies against the p67 antigen in patients with connective tissue diseases using the ELISA technique.
We have shown that antibodies to p67 above 5 U (mean+three SD of 46 normal subjects) were found in 8/10 (80%) patients with a clinical diagnosis of MCTD (based on only the clinical criteria of Sharp et al7). We also found increased levels in 27/67 (40%) patients with SLE, however, as well as 15% of patients with polymyositis/dermatomyositis, 8/48 (17%) with Raynaud's phenomenon and 1/46 (2%) healthy subjects. This confirms that antibodies against the p67 antigen are found in low titres in a wide spectrum of patients. '7 High levels of antibodies to p67 (defined as >50 U/ml) were found only in the patients with connective tissue diseases (5/10 (50%) patients with MCTD, 12/67 (18%) The patients with SLE with antibodies to p67 at any titre often have clinical features of MCTD, however, particularly myositis (80%). This implies that antibodies to p67 are not restricted to MCTD but are particularly associated with myositis, which may be found in patients with MCTD and SLE. This confirms a previous study which often found the presence of MCTD features in patients with SLE, '9 and suggests that these antibodies may be a useful marker for these features in either group. This is further corroborated by analysis of those patients with high titres of antibodies to p67 (table 4), as in this group of 12 patients with SLE 75% had myositis. The occurrence of other features of MCTD including sclerodactyly and reduced lung function was 75%, and all these patients had synovitis. In addition, the incidence of renal disease in these patients was similar in those with and without antibodies to RNP, which is in agreement with the data for the SLE group as a whole.
These results show that high levels of antibodies to p67 determined by ELISA are common in patients with MCTD but are also present in some patients with SLE. In this group of patients with SLE clinical features of MCTD are also seen, suggesting that the patients with SLE with antibodies to p67 form a subgroup of SLE/MCTD. 197-220.
